Cite
Tursi A, Mocci G, Allegretta L, et al. Comparison of Performances of Infliximab Biosimilars CT-P13 Versus SB2 in the Treatment of Inflammatory Bowel Diseases: A Real-Life Multicenter, Observational Study in Italy. Expert Opin Biol Ther. 2021;doi: 10.1080/14712598.2022.2007881.
Tursi, A., Mocci, G., Allegretta, L., Aragona, G., Bianco, M. A., Colucci, R., Cuomo, A., Della Valle, N., Ferronato, A., Forti, G., Gaiani, F., Graziani, M. G., Lorenzetti, R., Luzza, F., Paese, P., Penna, A., Pica, R., Pranzo, G., Rodinò, S., Scarcelli, A., Zampaletta, C., Brozzi, L., Cicerone, C., Cocco, A., De' Angelis, G., Donnarumma, L., Fiorella, S., Iannelli, C., Larussa, T., Le Grazie, M., Luppino, I., Meucci, C., FaggianI, R., Pagnini, C., Perazzo, P., Rodriguez-Castro, K. I., Sacco, R., Sebkova, L., Serio, M., De Monti, A., Picchio, M., Napolitano, D., Schiavoni, E., Turchini, L., Scaldaferri, F., Pugliese, D., Guidi, L., Laterza, L., Privitera, G., Pizzoferrato, M., Lopetuso, L. R., Armuzzi, A., Elisei, W., Maconi, G., & Papa, A. (2021). Comparison of Performances of Infliximab Biosimilars CT-P13 Versus SB2 in the Treatment of Inflammatory Bowel Diseases: A Real-Life Multicenter, Observational Study in Italy. Expert opinion on biological therapy, . https://doi.org/10.1080/14712598.2022.2007881
Tursi, Antonio, et al. "Comparison of Performances of Infliximab Biosimilars CT-P13 Versus SB2 in the Treatment of Inflammatory Bowel Diseases: A Real-Life Multicenter, Observational Study in Italy." Expert opinion on biological therapy vol. (2021). doi: https://doi.org/10.1080/14712598.2022.2007881
Tursi A, Mocci G, Allegretta L, Aragona G, Bianco MA, Colucci R, Cuomo A, Della Valle N, Ferronato A, Forti G, Gaiani F, Graziani MG, Lorenzetti R, Luzza F, Paese P, Penna A, Pica R, Pranzo G, Rodinò S, Scarcelli A, Zampaletta C, Brozzi L, Cicerone C, Cocco A, De' Angelis G, Donnarumma L, Fiorella S, Iannelli C, Larussa T, Le Grazie M, Luppino I, Meucci C, FaggianI R, Pagnini C, Perazzo P, Rodriguez-Castro KI, Sacco R, Sebkova L, Serio M, De Monti A, Picchio M, Napolitano D, Schiavoni E, Turchini L, Scaldaferri F, Pugliese D, Guidi L, Laterza L, Privitera G, Pizzoferrato M, Lopetuso LR, Armuzzi A, Elisei W, Maconi G, Papa A. Comparison of Performances of Infliximab Biosimilars CT-P13 Versus SB2 in the Treatment of Inflammatory Bowel Diseases: A Real-Life Multicenter, Observational Study in Italy. Expert Opin Biol Ther. 2021 Dec 14; doi: 10.1080/14712598.2022.2007881. Epub 2021 Dec 14. PMID: 34904510.
Copy
Download .nbib